Moneycontrol
HomeNewsBusinessMoneycontrol ResearchSun Pharma Q2 steady — Should investors pop the stock pill?
Trending Topics
Sensex Live
Pine Labs IPO Day 1
Groww IPO Day 3 GMP
Upcoming IPOs
Gold Rate

Sun Pharma Q2 steady — Should investors pop the stock pill?

Anubhav Sahu   •

While US generic sales would remain soft due to the reduced contribution of Revlimid, innovative medicine sales are expected to do well.

New offerings, such as Leqselvi & Unloxcyt, to help in H2

To read the full story,

Subscribe to Moneycontrol PRO
  • Ad-free Experience
  • Access Exclusive Stories
  • Weekly Investment Ideas
  • Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

  • Ad free Experience

    Seamless navigation, faster responses.

  • Expert Perspective

    Explore 230+ exclusive editorials every month

  • +

    Uncover Insights from World-Renowned Experts and Journalists

  • Actionable Insights

    40+ weekly investment ideas + 3 to 4 daily technical calls

  • Virtual Events

    Exclusive Live Webinars for Expert Trading & Investment Strategies!

  • Newsletters

    Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More